NervGen Doses First Patient in Late-Stage Study of Potential Spinal Cord Injury Treatment

07:48 AM EDT, 10/12/2026 (MT Newswires) -- NervGen (NGEN) has dosed the first participant in a phase 3 study of NVG-291 for the treatment of chronic cervical motor-incomplete spinal cord injury, the company said Monday. The study is expected to enroll about 150 participants across the US and Canada, with enrollment completion likely in H2 2027 and topline data expected in H1 2028. NervGen shares were down 1% in premarket activity.